US FDA Unlikely To Issue Broad Biosimilar Guidance Saying Comparative Clinical Studies Unnecessary

 
• By Derrick Gingery
Insulin vials
Sarah Yim said extensive research helped convince hesitant colleagues that comparative clinical trials were not needed for insulin biosimilars. • Source: Alamy

More from Biosimilars

More from Biosimilars & Generics